

# HCP, HCO and ORDM Transfer of Value Methodological Note

#### 1. Introduction

Incyte Biosciences UK Ltd (hereinafter referred to as "Incyte" or the "Company") fully supports the transparency requirements set out in the Association of the British Pharmaceutical Industry (ABPI) Code of Practice and is committed to making public the details of all transfers of value (ToV) made to healthcare professionals (HCPs), healthcare organisations (HCOs) and, other relevant decision makers (ORDMs).

This note describes the methods used by the company to meet the obligations for disclosing relevant ToVs within scope and includes a general summary of how the company collects and prepares this data.

#### 2. Definitions and scope

Incyte recognises HCPs, ORDMs, HCOs and ToV according to their definitions in the ABPI Code of Practice for the disclosure period.

**Transfer of Value** means a direct or indirect payment, whether in cash, in- kind, or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. Examples of ToV could include:

- Collaborative working, including joint working
- Donations and grants provided to healthcare organisations, institutions and other organisations
- Fees and expenses paid for contracted services between companies and institutions, organisations or associations of health professionals
- Support of attendance by HCPs and ORDMs at events/meetings
- Fees and expenses paid for contracted services to health professionals and other relevant decision makers, or to their employers on their behalf
- Sponsorship, including contributions to costs related to events/meetings paid to HCOs or to organisations managing events on their behalf, which may include support of HCPs and ORDMs not known to the company via the HCO by way of registration fees, accommodation and travel

**Healthcare Professional** includes members of the medical, pharmacy or nursing profession and any other person who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

**Other Relevant Decision Maker** include those in a role that could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply, or use of any medicine but who is not an HCP

**Healthcare Organisation** means a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address,

place of incorporation or primary place of operation is in Europe or an organisation through which one or more HCPs or ORDMs provide services.

Incyte has considered the ToV recipient to be the contracting entity, which may be an HCP, ORDM, a legal entity owned by an HCP (which is then an HCO) or an HCO. Hence the contracting party as stated on the legal contract for an activity executed between Incyte and the counterpart has been reported as the recipient.

ToV that relate to research and development (R&D) is disclosed as an aggregate figure.

ToV undertaken by other Incyte affiliates with UK HCPs, HCOs or ORDMS's will be disclosed.

### 3. Consent & data privacy

Incyte fully supports the principles of transparency and abides by data privacy law.

The company will disclose any ToV upon the lawful basis of pursuing its legitimate interests.

The company's legitimate interests must be balanced against the interests and rights of the recipient and in cases where consent to individual disclosure is withdrawn, all ToV with no consent to disclose are disclosed in the aggregate value.

HCPs or ORDMs may exercise the right to object to individual disclosure, in which case, they must promptly inform Incyte in writing at <u>Transparency UK@incyte.com</u> and Incyte will report the ToV in aggregate form.

## 4. Financial considerations & disclosure period

ToV to HCPs or ORDMs reflect fair market value, taking into account the nature of services rendered, the amount of time spent, and the knowledge and expertise of the HCP or ORDM.

The Company has made its disclosures in British pound sterling (GBP) and inclusive of all applicable taxes where applicable. Grants and Donations are excluding VAT.

Incyte discloses the ToV based on the date the payment was made to the HCP, HCO or ORDM.

For those payments made in any other currency, the company has applied the exchange rate with GBP at the time of payment.

This disclosure period covers all relevant ToV made by the company between 1 January and 31 December 2024, inclusive of both these dates.

#### 5. Disclosure publication

Incyte uses the centralised ABPI platform for UK disclosure.